Ginkgo Bioworks Holdings, Inc.
DNA· NYSE
Released Aug 5, 2026, after the close
10-Q filed Aug 6, 2026, 37 days after period end · 0001628280-26-054298
| Metric | Q2 2026 | Q2 2025 | Q2 2024 | Q2 2023 |
|---|---|---|---|---|
| Revenue | $20.16M | $39.13M | $56.21M | $80.57M |
| Net Income | -$46.71M | -$60.30M | -$217.18M | -$173.32M |
| EPS Diluted |
Ginkgo Bioworks Holdings, Inc. · CIK 1830214 · Engraved from SEC EDGAR
| — |
| -$1.10 |
| -$4.23 |
| -$0.09 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.